Ted Kim, PA-C, is a highly trained Physician Assistant dedicated to providing compassionate, evidence-based oncology care while advancing the future of cancer treatment through clinical research. His work bridges direct patient care with data-driven innovation, ensuring patients benefit from compassionate care and cutting-edge science.
At the Cancer Center of Southern California, Ted serves as a Clinician and Sub-Investigator on Phase I–III clinical trials, performing protocol-driven evaluations, safety monitoring, and regulatory-compliant study oversight. He plays an integral role in managing complex cancer cases, with a particular focus on solid tumors and sarcomas.
- Physician Assistant specializing in oncology and sarcoma care
- Sub-Investigator on Phase I–III oncology clinical trials
- Expertise in clinical trial operations, safety monitoring, and regulatory compliance
- Strong background in AI-driven and data-integrated cancer research
- Master of Science in Physician Assistant Studies, Stanford University School of Medicine
- Bachelor of Science in Physiological Sciences, University of California, Los Angeles
- Author and co-author of peer-reviewed manuscripts in oncology, precision medicine, and immunotherapy
- Contributor to national oncology conferences, including ASCO and CTOS
- Co-author of a book chapter on immune and cell cycle checkpoint inhibitors in cancer immunotherapy
He works closely with oncologists, research teams, and study coordinators to support clinical trial enrollment and execution. With more than five years of oncology research experience, Ted brings extensive expertise in clinical trial operations, translational science, and outcomes-focused oncology care.
He also worked closely with the Stanford Cancer Institute and the Stanford Sarcoma Program.
During his days at the Stanford University School of Medicine, he conducted research in the Department of Radiation Oncology within the Li Lab, leading projects integrating radiologic, pathologic, and clinical data to develop AI-driven models for predicting cancer outcomes, including melanoma relapse, pan-cancer prognosis, and immunotherapy response.
He has contributed to multiple peer-reviewed publications, including a 2025 Nature study on vision-language foundation models for precision oncology. His graduate thesis evaluating first-line systemic therapies for advanced leiomyosarcoma was presented in 2025 and subsequently published in Diseases. In addition to his academic work, Ted has co-authored multiple abstracts for the American Society of Clinical Oncology (ASCO) and the Connective Tissue Oncology Society (CTOS), collaborating on studies exploring novel immunotherapy combinations, targeted therapies, and emerging investigational agents.
For an appointment with our providers, please call us at 310-552-9999 or request an appointment online.
